Troubles behind it, Cadila surges ahead

Cadila hopes to double its revenue from the US in three years

The shares of pharma major Cadila Healthcare, also known as Zydus Cadila, have been on a roll for the past few weeks. The stock's value rose almost 55 per cent to a six-month high of Rs 548.35 on June 12. Cadila has edged past Lupin to become the second-most valuable pharmaceutical company by market capitalisation at Rs 54,719 crore.

There were two triggers behind this sharp rise; one, the US Food and Drug Administration’s approval for the generic version of an ulcerative colitis drug Lialda (which has sales of $ 1.14 billion in the US); and two, the expectation of